eligibility_summary
Eligible: women 18–75 with path-confirmed HR+/HER2‑low stage II–III breast cancer, treatment‑naive, ECOG 0–1, adequate organ function, informed consent and compliance. Exclude: prior/concurrent therapy, bilateral/inflammatory/occult or stage IV, unconfirmed pathology, other malignancy <5y (except cured cervical CIS and melanoma skin cancer), trial <4w, drug allergy, immunodeficiency, major CV disease, ILD, active hepatitis/cirrhosis, bleeding/thrombotic tendency, neuro/psychiatric disorders.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drugs/interventions: SHR-A1811 (antibody–drug conjugate, ADC) targeting HER2, Adebrelimab (anti–PD‑L1 monoclonal antibody, immune checkpoint inhibitor). Mechanisms: SHR-A1811 binds HER2 on tumor cells (including HER2‑low), is internalized, and releases a cytotoxic payload to kill cancer cells and disrupt HER2-driven signaling. Adebrelimab blocks PD‑L1, preventing PD‑1 engagement to reinvigorate antitumor T‑cell activity. Targeted cells/pathways: HER2-expressing breast cancer cells, PD‑L1–expressing tumor and immune cells, pathways include HER2 signaling and the PD‑1/PD‑L1 checkpoint, enhancing CD8+ T‑cell–mediated immunity.